Investor profile
ShangBay Capital
VC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
ShangBay Capital is a Palo Alto-based venture capital firm focused exclusively on medical devices, biopharma, and healthcare technology. The firm invests in founders who build disruptive companies addressing high, unmet clinical needs with novel ideas, leveraging a leadership team with over 100 combined years of industry experience and deep ties to strategics, KOLs, and innovators. ShangBay takes a hands-on, collaborative approach — actively helping portfolio companies commercialize products, navigate FDA regulatory pathways, and expand their business footprint — with the goal of bringing the most disruptive products to U.S. and global markets while delivering exceptional returns to investors.
Notable quotes
“This past year has underscored the profound impact that medical technology can have on improving patient outcomes. I feel privileged to contribute to this dynamic and meaningful field, working alongside innovators who are redefining what's possible in healthcare. As we look ahead, I remain committed to supporting the next generation of pioneering medtech companies.”
“I've spent the past 25 years doing a lot of deals and mergers and acquisitions work.”
“ShangBay Capital Founding Managing Partner William Dai draws on 30+ years in medtech — including a tenure at Boston Scientific — to reflect on what separates the roughly 5% of medtech startups that survive from those that don't, backing companies through the hardest phases of growth with a clear-eyed view of the road to commercialization and, ultimately, patients.”
Team
Chaucer Shen
Managing Partner
Erik T. Engelson
Venture Partner
Michael Wallace
Senior Technology Advisor
Rich Trimble
Senior Associate
Ethan Kau
Analyst
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Nervonik | Series B | — | 2026-04-27 |
| Petal Surgical | Series A | $10m | 2025-10-01 |
| SetPoint Medical | Series D | $120m | 2025-08-01 |
| Evident Vascular | Series B | — | 2025-03-25 |
| Fluid Biomed | Series A | — | 2024-12-16 |
| Inquis Medical | Series B | — | 2024-11-04 |
| Ceribell | IPO | — | 2024-10-11 |
| Noah Medical | Series B | $150m | 2023-04-20 |
| Luminopia | Seed | $6m | 2022-10-01 |
| Arrinex | Acquisition (Stryker) | — | 2019-02-25 |
Frequent co-investors
Fit check
Is ShangBay Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit